Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCL201 + Idelalisib in FL and MCL
NCT02603445Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Jul 2018
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 1, open-label trial of S55746 in follicular lymphoma (FL) and mantle cell lymphoma (MCL) (2 arms), sponsored by Novartis. Primary endpoint: Number of participants with adverse events (AEs) at 24 months. Started Nov 2015; status: completed.
02
Drugs
S55746
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02603445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603445.